Company intelligence / Profile preview

Skylighter

Leuven, Flanders, Belgium

Ownership: Private
Development stage: Other

Overview

Skylight Therapeutics is an early-stage drug discovery company that utilizes proprietary optical technologies, including Second Harmonic Generation (SHG) and Sum-Frequency Generation (SFG), to monitor real-time protein conformational changes. This platform enables the identification of allosteric binders and conformational modulators for difficult-to-drug targets in oncology and inflammation, such as IDO1 and KRAS.

Therapeutic areas: OncologyImmunology
Modalities: Small moleculeProteins
Industry: Biotech

Beyond the preview

Go deeper on Skylighter.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Skylighter.

Explore the full profile